SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects

被引：120
作者：
Lam, Carolyn S. P. [1 ,2 ,3 ,4 ]
Chandramouli, Chanchal [1 ]
Ahooja, Vineeta [5 ]
Verma, Subodh [6 ,7 ]
机构：
[1] Natl Heart Ctr Singapore, 5 Hosp Dr, Singapore 169609, Singapore
[2] Duke Natl Univ Singapore, Med Sch, Singapore, Singapore
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] George Inst Global Hlth, Newtown, Tas, Australia
[5] Heart Hlth Inst, Toronto, ON, Canada
[6] Univ Toronto, Keenan Res Ctr Biomed Sci, Div Cardiac Surg, St Michaels Hosp, Toronto, ON, Canada
[7] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada
来源：
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2019年 / 8卷 / 20期
关键词：
heart failure; SGLT-2; inhibitors; type 2 diabetes mellitus; unmet needs; ASSOCIATION TASK-FORCE; 2013 ACCF/AHA GUIDELINE; NONCARDIAC COMORBIDITIES; CARDIOVASCULAR OUTCOMES; AMERICAN-COLLEGE; DIABETES-MELLITUS; EJECTION FRACTION; NA+/H+-EXCHANGER; CARDIAC FIBROSIS; FOCUSED UPDATE;
D O I：
10.1161/JAHA.119.013389
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：12
相关论文
共 102 条
[1]   Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes [J].
Al-Jobori, Hussein ;
Daniele, Giuseppe ;
Cersosimo, Eugenio ;
Triplitt, Curtis ;
Mehta, Rucha ;
Norton, Luke ;
DeFronzo, Ralph A. ;
Abdul-Ghani, Muhammad .
DIABETES, 2017, 66 (07) :1999-2006
[2]  
[Anonymous], 2016, NAT HEART FAIL AUD 2
[3]   Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction [J].
Ather, Sameer ;
Chan, Wenyaw ;
Bozkurt, Biykem ;
Aguilar, David ;
Ramasubbu, Kumudha ;
Zachariah, Amit A. ;
Wehrens, Xander H. T. ;
Deswal, Anita .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (11) :998-1005
[4]   Chronic inhibition of the Na+/H+-exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling [J].
Baartscheer, A. ;
Hardziyenka, M. ;
Schumacher, C. A. ;
Belterman, C. N. W. ;
van Borren, M. M. G. J. ;
Verkerk, A. O. ;
Coronel, R. ;
Fiolet, J. W. T. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (06) :1266-1275
[5]   Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits [J].
Baartscheer, Antonius ;
Schumacher, Cees A. ;
Wust, Rob C. I. ;
Fiolet, Jan W. T. ;
Stienen, Ger J. M. ;
Coronel, Ruben ;
Zuurbier, Coert J. .
DIABETOLOGIA, 2017, 60 (03) :568-573
[6]  
Bloom DE., 2011, The global economic burden of noncommunicable diseases
[7]  
Bonaca MP, 2019, 68 ANN SCI SESS EXP
[8]   Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion [J].
Bonner, Caroline ;
Kerr-Conte, Julie ;
Gmyr, Valery ;
Queniat, Gurvan ;
Moerman, Ericka ;
Thevenet, Julien ;
Beaucamps, Cedric ;
Delalleau, Nathalie ;
Popescu, Iuliana ;
Malaisse, Willy J. ;
Sener, Abdullah ;
Deprez, Benoit ;
Abderrahmani, Amar ;
Staels, Bart ;
Pattou, Francois .
NATURE MEDICINE, 2015, 21 (05) :512-U139
[9]  
Byrne Nikole J, 2017, JACC Basic Transl Sci, V2, P347, DOI 10.1016/j.jacbts.2017.07.003
[10]   Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry [J].
Cavender, Matthew A. ;
Steg, Ph Gabriel ;
Smith, Sidney C., Jr. ;
Eagle, Kim ;
Ohman, E. Magnus ;
Goto, Shinya ;
Kuder, Julia ;
Im, Kyungah ;
Wilson, Peter W. F. ;
Bhatt, Deepak L. .
CIRCULATION, 2015, 132 (10) :923-931
12345678910